The largest drug companies are far more interested in enriching themselves and investors than in developing new drugs, according to a House committee report released Thursday that argues the industry can afford to charge Medicare less for prescriptions.
The report by the House Oversight and Reform Committee says that contrary to pharmaceutical industry arguments that large profits fund extensive research and innovation, the major drug companies plow more of their billions in earnings back into their own stocks, dividends and executive compensation.
And they can do it largely because Congress has imposed few restrictions on their pricing in the United States including in the Medicare program, which is not permitted to negotiate drug prices, House Democrats say.
Drugmakers spending on stock, dividends and executive pay exceeds research, democrats say
news-medical.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from news-medical.net Daily Mail and Mail on Sunday newspapers.
Big Pharma Spend More on Exective Pay and Dividends Than Research
truthout.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from truthout.org Daily Mail and Mail on Sunday newspapers.
Biogen Inc : Collaboration Between AbbVie, Biogen and Pfizer Creates World s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Market gears up for biosimilar boom in 2023 as Humira exclusivity draws to a close
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.